JSJonas Schreyögg

Jonas Schreyögg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonas Schreyögg has a total of 167 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patientensteuerung aus gesundheitsökonomischer Perspektive: Bedingungen wirksamer Kostenbeteiligung im europäischen Vergleich

    by Sebastian Böhme, Jessica Paas, Zoe Konjer, Jonas Meyrer, Jonas Schreyögg

    Zusammenfassung: Steigende Gesundheitsausgaben und der demografische Wandel stellen die Finanzierung und Steuerung gesundheitlicher Versorgung in Deutschland vor zunehmende Herausforderungen. Zuzahlungen werden in der gesundheitspolitischen Debatte regelmäßig als Instrument zur Reduktion von Fehlinanspruchnahme diskutiert, zuletzt im Kontext eines Primärarztsystems. Der vorliegende Beitrag analysiert die institutionelle Ausgestaltung und empirische Evidenz finanzieller Steuerungsinstrumente in 4 europäischen Gesundheitssystemen (Deutschland, Niederlande, Frankreich, Dänemark) und führt die Befunde in einer gesundheitsökonomischen Synthese zusammen. Die Wirksamkeit von Zuzahlungen erweist sich als Funktion dreier ineinandergreifender Bedingungen: der Leistungsart, der verhaltensökonomischen Ausgestaltung und der institutionellen Architektur. Uniforme Zuzahlungen wirken regressiv und belasten Versicherte mit geringem Einkommen überproportional. Eine Wiedereinführung der Praxisgebühr in ihrer früheren Form ist auf Basis der internationalen Evidenz nicht zu empfehlen. Sinnvoll erscheint hingegen eine Konstruktion, die Zuzahlungen als gezieltes Lenkungsinstrument an jenen Stellen einsetzt, an denen Fehlinanspruchnahme empirisch festgestellt wird, etwa beim unangemessenen Verlassen eines koordinierten Versorgungspfades. Voraussetzung ist eine Ausgestaltung, die verhaltensökonomische Effekte und einkommensbezogene Unterschiede berücksichtigt. So konzipiert können Zuzahlungen zur Verbesserung der Patientensteuerung beitragen, ohne den Zugang zur Regelversorgung zu gefährden.

  • Open Access

    „Verbindlichkeit ist die Voraussetzung für effektive Steuerung“

    by Jonas Schreyögg, Peter Stegmaier

    Techniker Krankenkasse has presented its evaluation of the TK HzV-Bund contracts in 13 German federal states, and a battle of interpretations promptly erupted. Health insurance funds and medical associations interpret the findings as evidence that GP programmes offer no benefit to insured persons. The man responsible for the study disagrees. Prof. Dr Jonas Schreyögg, Director of the Hamburg Centre for Health Economics (HCHE), which conducted the study, explains in an interview with “Monitor Versorgungsforschung” why the HzV does not control the model under investigation, but rather does so “only to a limited extent” , why he considers it a transitional phenomenon in its current form, and how a mandatory primary care model could reshape our healthcare system.

  • Assessing smoking cessation preferences in Germany: A discrete choice experiment

    by Kathleen Gali, Sebastian Himmler, Jonas Schreyögg

    Introduction: Smoking prevalence in Germany remains high (30%) and uptake of cessation services is low. E-cigarettes are promoted as a cessation aid but whether they are preferred over established methods is unknown. To improve cessation efforts, understanding the extent different characteristics of a smoking cessation program are preferred are important. This study estimated preferences and willingness-to-pay for a smoking cessation program using a discrete choice experiment (DCE). Methods: Potential participants who resided in Germany and smoked ≥5 cigarettes daily (cpd) were recruited for the main study between July-September 2023. The DCE included 12 choice tasks. Attributes were cessation aids (nicotine replacement, medication, and e-cigarettes), counseling, referral by a health professional, effectiveness, and out-of-pocket costs. Results: The study sample (N=1052) was 51.4% female with a mean cpd of 17 (SD=8.2). Mixed logit regression found counseling, referrals, and program effectiveness significantly influenced choices (p<0.001). None of the levels for cessation aids were significant. However, in subgroup analyses the use of e-cigarettes for quitting was preferred by those with prior e-cigarette use, while evidence-based cessation aids were preferred by several other subgroups. While low costs were preferred, particularly among those with no experience using cessation aids, participants were willing to pay a high cost for an effective program (€91.48/month). Conclusion: To increase engagement, smoking cessation programs in Germany should include counseling and be explicit on the evidence of cessation therapies, as program effectiveness is highly valued. Improving access to cessation aids through referrals and lower costs can increase cessation efforts. Implications: Our findings suggest that German adults who smoke are most likely to engage in cessation programs that demonstrate proven effectiveness, include counseling support, and are recommended by a health professional. The lack of preference for specific cessation aids, except e-cigarettes among prior users, indicates that better communication about the effectiveness of evidence-based pharmacotherapies is needed. Health professionals should provide clear, evidence-based guidance on all cessation methods, including transparent discussion of the current evidence regarding e-cigarettes for smoking cessation, to support informed decision-making and optimize treatment selection.

  • Open Access

    Surgeon Experience and Outcomes: Specific, Analogy-Based and Cumulative Learning in Cardiac Surgery

    by Benedikt L Langenbeck, Esra Eren Bayindir, Jonas Schreyögg, Tobias Becker, Jan F Gummert

    Objectives: To assess how different learning mechanisms, including specific learning, analogy-based learning, and cumulative experience, influence surgical outcomes following coronary artery bypass graft (CABG), aortic valve replacement (AVR), and mitral valve reconstruction (MVR) surgeries. Methods: Between 2010 and 2023, 46 surgeons performed 21 269 cardiac surgeries (CABG, AVR, and MVR) at a major heart surgery centre in Germany. Surgical proficiency was assessed using the 30-day risk-adjusted mortality rate (RAMR) and risk-adjusted re-thoracotomy rate (RARR), calculated for each surgeon and adjusted using EuroSCORE II. Linear regression models examined associations between learning mechanisms and surgical outcomes. Results: Higher procedure-specific volume in the preceding quarter was significantly associated with a lower 30-day RAMR for CABG, demonstrating a decline of 0.49 percentage points (95% CI, −0.88 to −0.10; P = .014). Furthermore, analogy-based learning demonstrated a significant cross-procedural effect for CABG, as prior-quarter volumes of technically related procedures (AVR and MVR) exhibited significant non-linear associations with 30-day RAMR. For MVR, greater cumulative experience significantly reduced the RARR (−0.295; 95% CI, −0.55 to −0.03; P = .028). No significant volume-outcome associations were observed for AVR. This analysis included 21 269 total procedures (12 706 CABG, 5477 AVR, and 3086 MVR) from 2010 to 2023. Surgeons had a mean specialist experience of 8.2 years (CABG), 10.3 years (AVR), and 11.9 years (MVR) and performed a mean of 12, 5.1, and 5.1 procedure-specific surgeries per quarter, respectively. Conclusions: Maintaining consistent, procedure-specific practice and accumulating experience are crucial for improving cardiac surgery outcomes.

  • Open Access

    Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany

    by Vittoria Ardito, Lasse Falk, Montserrat Gasol Boncompte, Caridad Pontes, James Robinson, Jonas Schreyögg, Oriana Ciani

    The European Medicines Agency (EMA) implemented ‘fast-track' programmes, like conditional marketing authorisations (CMA), where the benefits of immediate drugs’ availability outweigh the risks associated with incomplete evidence. However, payers in the European Union (EU) decide on medicines’ coverage based on clinical benefits assessment, cost-effectiveness and/or budget impact. We investigated differences in the time-to-access of drugs approved via CMA vis-à-vis standard marketing authorisation (SMA) in Italy, Germany, and Spain. CMA-licenced drugs from 2006 to 2022 were retrieved and matched with comparable SMA drugs. Collected data were as follows: marketing authorisation details, drug characteristics, pivotal trials’ characteristics and national reimbursement decision dates. Data sources included European Public Assessment Reports, and country-specific databases (Farmadati®, Lauer-Taxe®, BIFIMED). CMA drugs take longer, in days, to reach reimbursement compared to SMA drugs both in Italy (CMA: median 523, mean 635, standard deviation (SD 364; SMA: median 455, mean 497, SD 242) and Spain (CMA: median 691, mean 779, SD 456; SMA: median 534, mean 568, SD 273). Cox regressions and Kaplan-Meier survival analyses corroborate these findings. The EMA’s intent to accelerate access to promising medicines may be offset by longer timelines to secure national reimbursement in major EU nations.

  • Open Access

    Data-driven identification of outpatient-suitable procedures: a machine learning approach

    by Robert Messerle, Jonas Schreyögg

    Policymakers worldwide are encouraging a shift from inpatient to outpatient care to improve the efficiency of health systems. One of the first steps in such efforts typically involves allowing providers, often hospitals, to perform a designated list of procedures on an outpatient basis. However, determining which procedures are suitable for the hospital outpatient setting remains challenging and has traditionally relied on expert judgment and established practices. Our study advances this approach by employing supervised machine learning techniques to identify patterns in physician and expert decisions. We present a comprehensive classification of hospital procedures as either inpatient- or outpatient-suitable and use some methods of explainable AI methods to identify the main factors influencing these assessments. Our model achieves high accuracy (92%) and a robust area under the receiver operating characteristic curve (> 95%), assigning outpatient suitability scores to the entire German procedure catalog. These scores can easily be used with aggregate hospital data from different countries. To validate our approach, we applied the model to a surgical procedures shortlist from the OECD. Our findings provide decision-makers with a data-driven framework for developing targeted strategies to incentivize the provision of outpatient care.


  • Open Access

    Messung des Einflusses einer alternden Bevölkerung und anderer nachfrageseitiger Determinanten auf die Inanspruchnahme stationärer Leistungen

    by Jonas Krämer, Jonas Schreyögg

    Zusammenfassung: In Politik und Praxis wird häufig davon ausgegangen, dass die Nachfrage nach Gesundheitsleistungen mit der Alterung der Bevölkerung zunimmt und entsprechend eine Erhöhung der Inanspruchnahme unvermeidlich ist. In Deutschland stiegen die stationären Fallzahlen von einem im internationalen Vergleich hohen Ausgangsniveau von 16,5 Mio. im Jahr 2005 auf 19,5 Mio. im Jahr 2016, was den mit Abstand größten prozentualen Anstieg der Krankenhausaufnahmen unter den OECD-Ländern darstellt, obwohl die Bevölkerungszahl nahezu gleich geblieben ist (Statistisches Bundesamt 2015). Der starke Anstieg in diesem Zeitraum ist aus empirischer Sicht gut geeignet, den Effekt der Alterung der Bevölkerung und anderer nachfrageseitiger Faktoren auf die Fallzahlentwicklung zu untersuchen. Die meisten neueren Studien aus anderen Ländern kommen basierend auf State-of-the-Art-Methoden zu dem Schluss, dass nachfrageseitige oder patientenbezogene Faktoren nur eine begrenzte Rolle spielen und dass die Angebotsseite eine wichtigere Rolle für die Schwankungen und das Wachstum der Inanspruchnahme des Gesundheitswesens und der Ausgaben in entwickelten Volkswirtschaften spielt (Chandra et al. 2011; Finkelstein et al. 2016; Hsiao und Heller 2007). Dabei scheinen wichtige Unterschiede in den Effekten zwischen verschiedenen Sektoren des Gesundheitswesens zu existieren.